Medtronic Gets FDA OK for Overactive Bladder Treatment Study

Medtronic Inc. (MDT) said it has begun the InSite Trial, a post-market study of its commercially available InterStim treatment for overactive bladder and urinary retention, after receiving approval from the Food and Drug Administration.
CNN